The invention relates to new chimeric molecules involving in their structure, a combination of the extracellular domain (EC) of the FasL protein (alias CD95L, Apo-1L) and a domain enabling oligomerisation of this Fas Ligand (FasL) EC domain, such as the Ig-like domain of the gp190 receptor for the Leukemia Inhibitory Factor (LIF alias CD118), or involving in their structure variants of said domains. The invention also relates to compositions comprising the chimeric molecule defined herein and relates to the use of these chimeric molecules especially to trigger cytotoxic activity toward cells sensitive to FasL.
